Selected research
Industry Research
Severe Asthma Treatment Industry Research Report 2026
Market perspective
The global Severe Asthma Treatment market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Severe Asthma Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Severe Asthma Treatment is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Severe Asthma Treatment is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Severe Asthma Treatment include Teva Pharmaceutical, Suzhou Connect Biopharmaceuticals, Sanofi, Novartis, Roche, GlaxoSmithKline, AstraZeneca, Regeneron Pharmaceutical and Pieris Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Severe Asthma Treatment market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Severe Asthma Treatment Market by Company
Teva Pharmaceutical
Suzhou Connect Biopharmaceuticals
Sanofi
Novartis
Roche
GlaxoSmithKline
AstraZeneca
Regeneron Pharmaceutical
Pieris Pharma
Morphosys
Biosion
Avalo Therapeutics
AB Pharma
4D Pharma plc
Severe Asthma Treatment Segment by Type
lntravenous
Oral
Subcutaneous
lnhaled
Severe Asthma Treatment Segment by Application
Teenagers
Children
Adults
Severe Asthma Treatment Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Severe Asthma Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Severe Asthma Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Severe Asthma Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Severe Asthma Treatment manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Severe Asthma Treatment by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Severe Asthma Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- lntravenous
- Oral
- Subcutaneous
- lnhaled
Applications
- Teenagers
- Children
- Adults
Companies covered
- Teva Pharmaceutical
- Suzhou Connect Biopharmaceuticals
- Sanofi
- Novartis
- Roche
- GlaxoSmithKline
- AstraZeneca
- Regeneron Pharmaceutical
- Pieris Pharma
- Morphosys
- Biosion
- Avalo Therapeutics
- AB Pharma
- 4D Pharma plc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Severe Asthma Treatment Market Size (2021-2032)
- 2.2.2 Global Severe Asthma Treatment Sales (2021-2032)
- 2.2.3 Global Severe Asthma Treatment Market Average Price (2021-2032)
- 2.3 Severe Asthma Treatment by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 lntravenous
- 2.3.3 Oral
- 2.3.4 Subcutaneous
- 2.3.5 lnhaled
- 2.4 Severe Asthma Treatment by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Teenagers
- 2.4.3 Children
- 2.4.4 Adults
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Severe Asthma Treatment Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Severe Asthma Treatment Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Severe Asthma Treatment Revenue of Manufacturers (2021-2026)
- 3.4 Global Severe Asthma Treatment Average Price by Manufacturers (2021-2026)
- 3.5 Global Severe Asthma Treatment Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Severe Asthma Treatment, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Severe Asthma Treatment, Product Type & Application
- 3.8 Global Manufacturers of Severe Asthma Treatment, Established Date
- 3.9 Global Severe Asthma Treatment Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva Pharmaceutical
- 4.1.1 Teva Pharmaceutical Company Information
- 4.1.2 Teva Pharmaceutical Business Overview
- 4.1.3 Teva Pharmaceutical Severe Asthma Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Pharmaceutical Severe Asthma Treatment Product Portfolio
- 4.1.5 Teva Pharmaceutical Recent Developments
- 4.2 Suzhou Connect Biopharmaceuticals
- 4.2.1 Suzhou Connect Biopharmaceuticals Company Information
- 4.2.2 Suzhou Connect Biopharmaceuticals Business Overview
- 4.2.3 Suzhou Connect Biopharmaceuticals Severe Asthma Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Suzhou Connect Biopharmaceuticals Severe Asthma Treatment Product Portfolio
- 4.2.5 Suzhou Connect Biopharmaceuticals Recent Developments
- 4.3 Sanofi
- 4.3.1 Sanofi Company Information
- 4.3.2 Sanofi Business Overview
- 4.3.3 Sanofi Severe Asthma Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Sanofi Severe Asthma Treatment Product Portfolio
- 4.3.5 Sanofi Recent Developments
- 4.4 Novartis
- 4.4.1 Novartis Company Information
- 4.4.2 Novartis Business Overview
- 4.4.3 Novartis Severe Asthma Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Novartis Severe Asthma Treatment Product Portfolio
- 4.4.5 Novartis Recent Developments
- 4.5 Roche
- 4.5.1 Roche Company Information
- 4.5.2 Roche Business Overview
- 4.5.3 Roche Severe Asthma Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Roche Severe Asthma Treatment Product Portfolio
- 4.5.5 Roche Recent Developments
- 4.6 GlaxoSmithKline
- 4.6.1 GlaxoSmithKline Company Information
- 4.6.2 GlaxoSmithKline Business Overview
- 4.6.3 GlaxoSmithKline Severe Asthma Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 GlaxoSmithKline Severe Asthma Treatment Product Portfolio
- 4.6.5 GlaxoSmithKline Recent Developments
- 4.7 AstraZeneca
- 4.7.1 AstraZeneca Company Information
- 4.7.2 AstraZeneca Business Overview
- 4.7.3 AstraZeneca Severe Asthma Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 AstraZeneca Severe Asthma Treatment Product Portfolio
- 4.7.5 AstraZeneca Recent Developments
- 4.8 Regeneron Pharmaceutical
- 4.8.1 Regeneron Pharmaceutical Company Information
- 4.8.2 Regeneron Pharmaceutical Business Overview
- 4.8.3 Regeneron Pharmaceutical Severe Asthma Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Regeneron Pharmaceutical Severe Asthma Treatment Product Portfolio
- 4.8.5 Regeneron Pharmaceutical Recent Developments
- 4.9 Pieris Pharma
- 4.9.1 Pieris Pharma Company Information
- 4.9.2 Pieris Pharma Business Overview
- 4.9.3 Pieris Pharma Severe Asthma Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Pieris Pharma Severe Asthma Treatment Product Portfolio
- 4.9.5 Pieris Pharma Recent Developments
- 4.10 Morphosys
- 4.10.1 Morphosys Company Information
- 4.10.2 Morphosys Business Overview
- 4.10.3 Morphosys Severe Asthma Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Morphosys Severe Asthma Treatment Product Portfolio
- 4.10.5 Morphosys Recent Developments
- 4.11 Biosion
- 4.11.1 Biosion Company Information
- 4.11.2 Biosion Business Overview
- 4.11.3 Biosion Severe Asthma Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Biosion Severe Asthma Treatment Product Portfolio
- 4.11.5 Biosion Recent Developments
- 4.12 Avalo Therapeutics
- 4.12.1 Avalo Therapeutics Company Information
- 4.12.2 Avalo Therapeutics Business Overview
- 4.12.3 Avalo Therapeutics Severe Asthma Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Avalo Therapeutics Severe Asthma Treatment Product Portfolio
- 4.12.5 Avalo Therapeutics Recent Developments
- 4.13 AB Pharma
- 4.13.1 AB Pharma Company Information
- 4.13.2 AB Pharma Business Overview
- 4.13.3 AB Pharma Severe Asthma Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 AB Pharma Severe Asthma Treatment Product Portfolio
- 4.13.5 AB Pharma Recent Developments
- 4.14 4D Pharma plc
- 4.14.1 4D Pharma plc Company Information
- 4.14.2 4D Pharma plc Business Overview
- 4.14.3 4D Pharma plc Severe Asthma Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 4D Pharma plc Severe Asthma Treatment Product Portfolio
- 4.14.5 4D Pharma plc Recent Developments
5 Global Severe Asthma Treatment Market Scenario by Region
- 5.1 Global Severe Asthma Treatment Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Severe Asthma Treatment Sales by Region: 2021-2032
- 5.2.1 Global Severe Asthma Treatment Sales by Region: 2021-2026
- 5.2.2 Global Severe Asthma Treatment Sales by Region: 2027-2032
- 5.3 Global Severe Asthma Treatment Revenue by Region: 2021-2032
- 5.3.1 Global Severe Asthma Treatment Revenue by Region: 2021-2026
- 5.3.2 Global Severe Asthma Treatment Revenue by Region: 2027-2032
- 5.4 North America Severe Asthma Treatment Market Facts & Figures by Country
- 5.4.1 North America Severe Asthma Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Severe Asthma Treatment Sales by Country (2021-2032)
- 5.4.3 North America Severe Asthma Treatment Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Severe Asthma Treatment Market Facts & Figures by Country
- 5.5.1 Europe Severe Asthma Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Severe Asthma Treatment Sales by Country (2021-2032)
- 5.5.3 Europe Severe Asthma Treatment Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Severe Asthma Treatment Market Facts & Figures by Country
- 5.6.1 Asia Pacific Severe Asthma Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Severe Asthma Treatment Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Severe Asthma Treatment Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Severe Asthma Treatment Market Facts & Figures by Country
- 5.7.1 South America Severe Asthma Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Severe Asthma Treatment Sales by Country (2021-2032)
- 5.7.3 South America Severe Asthma Treatment Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Severe Asthma Treatment Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Severe Asthma Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Severe Asthma Treatment Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Severe Asthma Treatment Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Severe Asthma Treatment Sales by Type (2021-2032)
- 6.1.1 Global Severe Asthma Treatment Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Severe Asthma Treatment Sales Market Share by Type (2021-2032)
- 6.2 Global Severe Asthma Treatment Revenue by Type (2021-2032)
- 6.2.1 Global Severe Asthma Treatment Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Severe Asthma Treatment Revenue Market Share by Type (2021-2032)
- 6.3 Global Severe Asthma Treatment Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Severe Asthma Treatment Sales by Application (2021-2032)
- 7.1.1 Global Severe Asthma Treatment Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Severe Asthma Treatment Sales Market Share by Application (2021-2032)
- 7.2 Global Severe Asthma Treatment Revenue by Application (2021-2032)
- 7.2.1 Global Severe Asthma Treatment Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Severe Asthma Treatment Revenue Market Share by Application (2021-2032)
- 7.3 Global Severe Asthma Treatment Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Severe Asthma Treatment Value Chain Analysis
- 8.1.1 Severe Asthma Treatment Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Severe Asthma Treatment Production Mode & Process
- 8.2 Severe Asthma Treatment Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Severe Asthma Treatment Distributors
- 8.2.3 Severe Asthma Treatment Customers
9 Global Severe Asthma Treatment Analyzing Market Dynamics
- 9.1 Severe Asthma Treatment Industry Trends
- 9.2 Severe Asthma Treatment Industry Drivers
- 9.3 Severe Asthma Treatment Industry Opportunities and Challenges
- 9.4 Severe Asthma Treatment Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst